GSK-Pfizer Backed HIV-Focused Unit ViiV Healthcare's Cabotegravir Injected Drug, Tablets Secure European Backing For Approval
Portfolio Pulse from Vandana Singh
ViiV Healthcare, majority owned by GSK plc and Pfizer Inc, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, recommending marketing authorization for cabotegravir long-acting (LA) injectable and tablets for HIV prevention. The positive opinion is supported by data from two international phase 2b/3 studies, HPTN 083 and HPTN 084.
July 24, 2023 | 12:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's majority-owned unit ViiV Healthcare has received European backing for its HIV prevention drug, which could potentially boost its revenues.
The positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use is a significant step towards the marketing authorization of cabotegravir. This could potentially increase the revenues of GSK, which is a majority owner of ViiV Healthcare.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Pfizer, which is a part-owner of ViiV Healthcare, could potentially benefit from the European backing for the HIV prevention drug cabotegravir.
The positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use is a significant step towards the marketing authorization of cabotegravir. This could potentially increase the revenues of Pfizer, which is a part-owner of ViiV Healthcare.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70